Oura Files for IPO Amid Rapid Revenue Growth and Expanding User Base

Oura, the company behind the biometric-tracking smart ring, has submitted a filing with the Securities and Exchange Commission signaling its intent to go public. The filing reveals a substantial increase in revenue, rising from $697 million in the nine months ending June 30 last year to $1.2 billion in the same period this year. The company has previously projected revenues of $500 million in 2024, about $1 billion in 2025, and close to $2 billion for the current year. The company reports having sold 3.6 million rings over the past year and currently maintains approximately 5 million paid subscribers who use its health monitoring services. Oura also highlights a strong membership retention rate of around 85% over 12 months, indicating sustained user engagement. Oura’s rings, priced between $350 and $400, function primarily as fitness trackers that monitor various biometrics such as metabolism, heart rate, stress, and sleep patterns. These devices work in conjunction with an app, forming what Oura describes as an "always-on health intelligence platform." Founded in Finland in 2013, Oura confidentially filed for an initial public offering in May. Reports suggest the company is targeting a $3 billion raise and a valuation near $16 billion, up from approximately $11 billion last year. In its SEC filing, Oura outlines plans to expand beyond traditional fitness tracking by increasing accessibility, building clinical validation, and integrating more deeply with healthcare providers, employers, and health plans. The company emphasizes its extensive biometric dataset, which includes nearly 42 billion hours of physiological data across more than 50 health metrics. This data underpins Oura’s AI and machine learning models, which aim to enhance accuracy and personalization over time. Despite its growth, Oura faces legal challenges. A proposed class action lawsuit alleges the company misled users about the accuracy of its sleep tracking, claiming the rings rely on AI-generated estimates rather than direct physiological signals. Oura has denied these allegations and stated it will defend itself in court. With offices worldwide, including San Francisco, Oura’s public offering will be closely watched as the company seeks to capitalize on growing interest in wearable health technology and AI-driven health insights.